



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



ELSEVIER

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.intl.elsevierhealth.com/journals/dema

Letter to Editor

Fast and simple high-throughput testing of COVID 19



The outbreak of the new coronavirus SARS-CoV-2 is a significant challenge for the analytical performance of laboratories [1,2]. In addition to the test capacity, this service also includes coping with requirements for increased supply of the necessary reagents.

We hereby present, in outline, a fast and easily workable alternative to our current RNA purification method for circumstances where there is limited availability of test kits. We

also report on the increase of test capacity without modifying the equipment pool. This *Munich Extraction Protocol (MEP)* approach draws upon first principles of molecular biology that are in danger of being lost due to the normal availability of ready-to-use kits.

Nasal and throat swabs that are transported in a special liquid viral medium to the laboratory were used. An aliquot of the sample was transferred into a cavity of a 96-well plate.

Samples		
Color	Name	Cp
Green	A1 Unverdünt Chemagen	18.51
Green	B1 1:10	23.20
Green	C1 1:100	26.23
Green	D1 1:1000	29.59
Green	E1 1:10000	32.78
Green	F1 1:100000	37.38
Green	G1 1:1000000	
Green	H1 1:10000000	
Red	A3 Unverdünt MEP	22.08
Red	B3 1:10	27.86
Red	C3 1:100	31.90
Red	D3 1:1000	35.96
Red	E3 1:10000	38.98
Red	F3 1:100000	
Red	G3 1:1000000	
Red	H3 1:10000000	
Blue	A5 Unverdünt MP96	16.96
Blue	B5 1:10	21.64
Blue	C5 1:100	25.56
Blue	D5 1:1000	29.81
Blue	E5 1:10000	33.67
Blue	F5 1:100000	37.10
Blue	G5 1:1000000	
Blue	H5 1:10000000	
Light Blue	A12 neg	
Light Blue	H12 pos Wu	27.67




Fig. 1 – The amplification curves of the different preparation protocols (right side) and the corresponding dilution levels (left side; green: Chemagic Viral Kit, red: MEP; blue: MagNA Pure 96) are shown.

When using the undiluted sample, an increase in fluorescence was observed with the commercial kits from about 15 cycles. When using the MEP, this increase was observed after about 20 cycles. At this number of cycles an increase of the fluorescence signal of the first dilution stage (1:10) could be measured when using the commercial kits. When using the MEP, approximately 1:10 of the template RNA is used compared to the commercial kits.

SARS-CoV-2 RNA extraction was performed either with two commercially available tests (MagNA Pure 96 Roche Diagnostics (Penzberg, Germany) and the Chemagic Viral DNA/RNA 300 Kit H96 (PerkinElmer Chemagen Technologie, Baesweiler, Germany); both tests require about 60 min per 96 samples). In addition we tested a fast method, which is based on a dilution step and heating to 92 °C for 10 min. The amplification was done in a Roche LightCycler® 480 II with an RIDA®GENE SARS-CoV-2 RUO assay from R-Biopharm.

Despite significant time saving and the use of readily available reagents, clinically acceptable sensitivity losses were seen with our “Munich Extraction Protocol (MEP)” (Fig. 1).

With the commercial kits one dilution level better sensitivity could be measured. One reason is that a 10-fold higher amount of template RNA can be used in these kits. This reduction in the amount of RNA used is due to the fact that commercial kits use purified RNA, whereas we use matrix-contaminated RNA. In this case it is common practice to reduce the amount of material used in order to avoid inhibition. We noticed that while the MEP method perfectly performs with standard samples a delay of crossing point (CP) values is observed with samples contaminated with hemoglobin.

Due to the much shorter extraction time using MEP, the test capacity can readily be increased by a factor of four.

In a further experiment we transferred aliquots from four 96-well plates to one 384-well plate and adapted the real-time PCR protocol according to [3]. The number of positive cases remained the same for both methods.

The presented modifications in the analytical process enable laboratories to increase their independence from potential reagent supply bottlenecks and to increase the test capacity without major modifications in the laboratory workflow. The medical quality is maintained.

We will be pleased to provide interested colleagues with the detailed methodological protocol.

REFERENCES

- [1] Salathe M, Althaus CL, Neher R, Stringhini S, Hodcroft E, Fellay J, et al. Covid-19 epidemic in switzerland: on the importance of testing, contact tracing and isolation. *Swiss Med Wkly* 2020;150:w20225.
- [2] Binnicker MJ. Emergence of a novel coronavirus disease (covid-19) and the importance of diagnostic testing: why partnership between clinical laboratories, public health

agencies, and industry is essential to control the outbreak. *Clin Chem* 2020.

- [3] Czibere L, Burggraf S, Fleige T, Gluck B, Keitel LM, Landt O, et al. High-throughput genetic newborn screening for spinal muscular atrophy by rapid nucleic acid extraction from dried blood spots and 384-well qpcr. *Eur J Hum Genet* 2020;28:23–30.

Jürgen Durner ^{a,b,*}

^a Laboratory Becker & Colleagues, Führichstr. 70, 81671 Munich, Germany

^b Department of Operative/Restorative Dentistry, Periodontology and Pedodontics, Ludwig-Maximilians-Universität München, Goethestr. 70, 80336 Munich, Germany

Siegfried Burggraf¹

Ludwig Czibere

Tobias Fleige

Arleta Madejska

Laboratory Becker & Colleagues, Führichstr. 70, 81671 Munich, Germany

David C. Watts

School of Medical Sciences and Photon Science Institute, University of Manchester, UK

Frank Krieg-Schneider

R-Biopharm AG, An der neuen Bergstraße 17, 64297 Darmstadt, Germany

Marc Becker^{a,b}

^a Laboratory Becker & Colleagues, Führichstr. 70, 81671 Munich, Germany

^b Department of Operative/Restorative Dentistry, Periodontology and Pedodontics, Ludwig-Maximilians-Universität München, Goethestr. 70, 80336 Munich, Germany

* Corresponding author at: Department of Conservative Dentistry and Periodontology, University Hospital, Ludwig-Maximilians-University Munich, Goethestraße 70, 80336 Munich, Germany.

E-mail address: juergen.durner@med.uni-muenchen.de (J. Durner)

¹ Both authors contributed equally to this paper.

0109-5641/© 2020 The Academy of Dental Materials. Published by Elsevier Inc. All rights reserved.

<https://doi.org/10.1016/j.dental.2020.04.001>